Generic drug: omacetaxine mepesuccinate
Brand name: Synribo
What is Synribo (omacetaxine mepesuccinate), and how does it work?
Synribo is a prescription medicine used to treat adults with a type of blood cancer called chronic myeloid leukemia (CML):
- that is in the chronic phase or accelerated phase, and
- who have not responded to (resistant) or cannot tolerate 2 or more medicines called tyrosine kinase inhibitors.
It is not known if Synribo is safe and effective in children.
What are the side effects of Synribo?
Synribo can cause serious side effects including:
- Low blood counts. Low blood counts are common when
using Synribo, including low red blood cells, white blood cells, and platelets,
and can be severe. If your white blood cell count becomes very low, you are at
increased risk for infection which can lead to death. Your healthcare provider
will check your blood counts regularly during treatment with Synribo. Tell your
healthcare provider right away if you get any of the following symptoms:
- fever
- chills
- body aches
- feeling very tired
- shortness of breath
- bleeding (see below)
- Bleeding. Synribo causes severe low platelet
counts that may increase your risk of severe bleeding. Severe low platelet
counts can cause you to have bleeding in your brain that can lead to death, or
severe stomach bleeding. Your healthcare provider will check your platelet
counts regularly during treatment with Synribo. Tell your healthcare provider
right away if you get any of the following symptoms:
- unusual bleeding
- easy bruising
- blood in urine or stool
- confusion
- slurred speech
- vision changes
The most common side effects of Synribo include:
- infections,
- diarrhea,
- nausea,
- tiredness,
- weakness,
- redness, swelling, or pain at injection site; and
- fever.
Tell your healthcare provider or get medical help right away if you get nausea, diarrhea, stomach (abdominal) pain, severe or worsening skin rash, or itching that does not go away.
You may have hair loss during treatment with Synribo. Synribo may cause fertility problems in males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.
These are not all of the side effects of Synribo.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is the dosage for Synribo?
Induction Schedule
- The recommended starting schedule for induction is 1.25 mg/m² administered subcutaneously twice daily at approximately 12 hour intervals for 14 consecutive days every 28 days, over a 28-day cycle.
- Cycles should be repeated every 28 days until patients achieve a hematologic response.
Maintenance Dosing
- The recommended maintenance schedule is 1.25 mg/m² administered subcutaneously twice daily at approximately 12 hour intervals for 7 consecutive days every 28 days, over a 28-day cycle.
- Treatment should continue as long as patients are clinically benefiting from therapy.
Dose Adjustments And Modifications
Hematologic Toxicity
- Synribo treatment cycles may be delayed and/or the number of days of dosing during the cycle reduced for hematologic toxicities (e.g. neutropenia, thrombocytopenia).
- Perform complete blood counts (CBCs) weekly during induction and initial maintenance cycles.
- After initial maintenance cycles, monitor CBCs every two weeks or as clinically indicated.
- If a patient experiences Grade 4 neutropenia (absolute neutrophil count (ANC) less than 0.5 x 109/L) or Grade 3 thrombocytopenia (platelet counts less than 50 x 109/L) during a cycle, delay starting the next cycle until ANC is greater than or equal to 1.0 x 109/L and platelet count is greater than or equal to 50 x 109/L. Also, for the next cycle, reduce the number of dosing days by 2 days (e.g. to 12 or 5 days).
Non-Hematologic Toxicity
- Manage other clinically significant non-hematologic toxicity symptomatically. Interrupt and/or delay Synribo until toxicity is resolved.
Is Synribo safe to use while pregnant or breastfeeding?
- Based on its mechanism of action and findings from animal studies, Synribo can cause fetal harm when administered to pregnant women.
- There are no available data on Synribo use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
- There are no data on the presence of omacetaxine mepesuccinate in either human or animal milk, the effects on the breastfed child, or the effects on milk production.
- Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with Synribo, and for 2 weeks after the final dose.

QUESTION
What is leukemia? See AnswerSummary
Synribo is a prescription medicine used to treat adults with a type of blood cancer called chronic myeloid leukemia (CML) that is in the chronic phase or accelerated phase, and who have not responded to (resistant) or cannot tolerate 2 or more medicines called tyrosine kinase inhibitors. Serious side effects of Synribo include low blood counts and bleeding.
Multimedia: Slideshows, Images & Quizzes
-
Cancer: Guide to Leukemia
Learn about the common types and stages of leukemia, who gets it, symptoms, tests, treatments, and more. People with blood cancer...
-
Blood Cancer Types: Leukemia, Lymphomas, Myelomas, and More
Types of blood cancers include leukemia, lymphomas, multiple myelomas, and others discussed in this slideshow. Symptoms may...
-
Leukemia Quiz
What do you know about leukemia? Did you know there are different types? What are the symptoms? Take the Leukemia Quiz and test...
Related Disease Conditions
-
Leukemia
Leukemia is a type of cancer of the blood cells in which the growth and development of the blood cells are abnormal. Strictly speaking, leukemia should refer only to cancer of the white blood cells (the leukocytes) but in practice, it can apply to malignancy of any cellular element in the blood or bone marrow, as in red cell leukemia (erythroleukemia).
-
What Is the Life Expectancy of a Person With Leukemia?
Leukemia is a group of cancers of the blood affecting the white blood cells. White blood cells are the infection-fighting cells of the body. In adults, leukemia is most common in people older than 55 years, with the average age of diagnosis being 66 years. It is also one of the most common cancers in children and adults younger than 20 years. The survival rate is higher for younger people.
-
How Does Leukemia Kill?
Leukemia is a cancer of the white blood cells of the bone marrow. Patients with leukemia have an over-production of a particular blood cell type in the body, the white blood cells (cells that fight infection, and provide immunity).
-
Survival Rate for Acute Lymphoblastic Leukemia
The prognosis depends on the type of leukemia, the extent of the disease, age of the patient, and the general condition of the patient. Some patients can go into complete remission. The average five-year survival rate of leukemia is 60-65%.
-
Leukemia: Signs, Symptoms, And Complications
Leukemia results when the genetic material (DNA) of a single cell in the bone marrow transforms, this is called a mutation. A mutated cell does not perform body function, but it eats away the nutrition meant for the normal cells.
-
What Are the Stages of Chronic Lymphocytic Leukemia?
Chronic lymphocytic leukemia is a cancer of the blood and bone marrow. With this type of cancer, the marrow creates too many abnormal lymphocytes. There are five stages of chronic lymphocytic leukemia.
Treatment & Diagnosis
- Leukemia FAQs
- Evolution of Treatment for a Rare Type of Leukemia
- Gleevec and Chronic Myeloid Leukemia
- How Familes Cope with a Leukemia Diagnosis
- Coping with a Bad Disease - Community Counts
- A Family's Leukemia Diary - Coping
- Is Multiple Myeloma the Same as Leukemia?
- Does Folic Acid Prevent Leukemia?
- Can Folic Acid Prevent Leukemia?
- Chronic Myelogenous Leukemia (CML)
Medications & Supplements
Health Solutions From Our Sponsors

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.